Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17183756 | 0.86 | HTR2A (0.41) | HTR2ACSNK1EOPRM1OPRD1OPRK1 | |
| SCHEMBL11896274 | 0.86 | HTR2A (0.41) | HTR2ACSNK1EOPRM1OPRD1OPRK1 | |
| SCHEMBL17183733 | 0.86 | HTR2A (0.41) | HTR2ACSNK1EOPRM1OPRD1OPRK1 | |
| SCHEMBL17183731 | 0.86 | HTR2A (0.41) | HTR2ACSNK1EOPRM1OPRD1OPRK1 | |
| SCHEMBL17183673 | 0.86 | HTR2A (0.41) | HTR2ACSNK1EOPRM1OPRD1OPRK1 | |
| SCHEMBL27608809 | 0.86 | HTR2A (0.41) | HTR2ACSNK1EOPRM1OPRD1OPRK1 | |
| SCHEMBL17183791 | 0.86 | HTR2A (0.41) | HTR2ACSNK1EOPRM1OPRD1OPRK1 | |
| SCHEMBL4635969 | 0.84 | SIGMAR1 (0.41) | HTR2ACSNK1EOPRM1OPRD1OPRK1 | |
| SCHEMBL7642935 | 0.80 | HTR2A (0.40) | HTR2ACSNK1EOPRM1OPRD1OPRK1 | |
| SCHEMBL7642931 | 0.80 | HTR2A (0.40) | HTR2ACSNK1EOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207416-B1 | ENHANCED RETENTION CAPABILITIES THROUGH METHODS COMPRISING SURFACE TREATMENT OF FUNCTIONAL PARTICULATE CARRIER MATERIALS, AND FUNCTIONAL PARTICULATE CARRIER MATERIALS MADE THEREFROM | IMERYS FILTRATION MINERALS INC (US) | 2018-11-07 | — | — | EP | disclosed |
| EP-2179019-B1 | ANTI-MICROBIAL COMPOSITION | BYOTROL PLC (GB) | 2016-12-14 | — | — | EP | disclosed |
| EP-2190962-B1 | FORMULATIONS COMPRISING AN ANTI-MICROBIAL COMPOSITION | BYOTROL PLC (GB) | 2015-02-25 | — | — | EP | disclosed |
| US-8598106-B2 | Anti-microbial composition exhibiting residual anti-microbial properties on a surface | BYOTROL PLC (GB) | 2013-12-03 | — | — | US | disclosed |
| US-8575085-B2 | Anti-microbial composition comprising a quaternary ammonium biocide and organopolysiloxane mixture | BYOTROL PLC (GB) | 2013-11-05 | — | — | US | disclosed |
| CN-101802159-B | Anti-microbial composition | BYOTROL PLC | 2013-03-27 | — | — | CN | disclosed |
| US-8178484-B2 | Anti-microbial composition comprising a siloxane and anti-microbial compound mixture | BYOTROL PLC (GB) | 2012-05-15 | — | — | US | disclosed |
| US-20120071525-A1 | ANTI-MICROBIAL COMPOSITION | BYOTROL PLC (GB) | 2012-03-22 | — | — | US | disclosed |
| US-20110263665-A1 | FORMULATIONS COMPRISING AN ANTI-MICROBIAL COMPOSITION | BYOTROL PLC (GB) | 2011-10-27 | — | — | US | disclosed |
| US-8003593-B2 | Formulations comprising an anti-microbial composition | BYOTROL PLC (GB) | 2011-08-23 | — | — | US | disclosed |
| US-20100279906-A1 | FORMULATIONS COMPRISING AN ANTI-MICROBIAL COMPOSITION | BYOTROL PLC (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100239679-A1 | ENHANCED RETENTION CAPABILITIES THROUGH METHODS COMPRISING SURFACE TREATMENT OF FUNCTIONAL PARTICULATE CARRIER MATERIALS, AND FUNCTIONAL PARTICULATE CARRIER MATERIALS MADE THEREFROM | WORLD MINERALS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| CN-101802159-A | Antimicrobial composition | BYOTROL PLC | 2010-08-11 | — | — | CN | disclosed |
| US-20100197748-A1 | ANTI-MICROBIAL COMPOSITION | BYOTROL PLC (GB) | 2010-08-05 | — | — | US | disclosed |
| EP-2207416-A1 | ENHANCED RETENTION CAPABILITIES THROUGH METHODS COMPRISING SURFACE TREATMENT OF FUNCTIONAL PARTICULATE CARRIER MATERIALS, AND FUNCTIONAL PARTICULATE CARRIER MATERIALS MADE THEREFROM | World Minerals, Inc. (US) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009045941-A1 | ENHANCED RETENTION CAPABILITIES THROUGH METHODS COMPRISING SURFACE TREATMENT OF FUNCTIONAL PARTICULATE CARRIER MATERIALS, AND FUNCTIONAL PARTICULATE CARRIER MATERIALS MADE THEREFROM | WORLD MINERALS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| US-20060276339-A1 | Methods and compositions for increasing the efficacy of biologically-active ingredients | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071525-A1 | ANTI-MICROBIAL COMPOSITION | H1-0, H1-3, H1-2 | HTR2A 3572/4885CSNK1E 1832/4885OPRM1 884/4885 |
| US-20110263665-A1 | FORMULATIONS COMPRISING AN ANTI-MICROBIAL COMPOSITION | PHOSPHO1, NAPEPLD, CAPG | HTR2A 4754/4885CSNK1E 4166/4885OPRM1 3219/4885 |
| US-20100197748-A1 | ANTI-MICROBIAL COMPOSITION | H1-0, H1-3, H1-2 | HTR2A 4301/4885CSNK1E 1904/4885OPRM1 1200/4885 |
| US-20060276339-A1 | Methods and compositions for increasing the efficacy of biologically-active ingredients | ENPP1, ENPP3, SMPD1 | HTR2A 4625/4885CSNK1E 2578/4885OPRM1 4792/4885 |
| US-20100279906-A1 | FORMULATIONS COMPRISING AN ANTI-MICROBIAL COMPOSITION | PHOSPHO1, NAPEPLD, CAPG | HTR2A 4754/4885CSNK1E 4166/4885OPRM1 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.